Compared to smokers alone, smokers with co-morbid substance use disorders are at greater risk of suffering from smoking-related death. Despite this, relatively few studies have examined smoking cessation treatments for those with stimulant dependence. In the current study, we sought to evaluate the effects produced by short-term exposure to the cholinesterase inhibitor rivastigmine (0, 3 or 6 mg) on cigarette smoking in nontreatment-seeking, methamphetamine-dependent volunteers. This was a double-blind, placebo-controlled, crossover study that took place over 9 days. The data indicate that rivastigmine treatment did not alter Fagerström Test for Nicotine Dependence scores, carbon monoxide readings, or cigarettes smoked per day, but a trend toward reduced urges to smoke (p b 0.09) was detected during treatment with rivastigmine 3 mg. These data, while preliminary, indicate that cholinesterase inhibitors warrant consideration as treatments for nicotine dependence, including use in stimulant-dependent individuals who exhibit significantly higher rates of smoking than the general population.
Introduction
Cigarette smoking is the leading cause of death and morbidity in the US (Centers for Disease Control and Prevention, 2008) . Among those with substance use disorders, rates of smoking are almost 70%, approximately 3-to 4-fold greater than the general population (Kalman et al., 2005) . Even higher rates of smoking, 87-92%, are reported among those with methamphetamine-dependence (Weinberger and Sofuoglu, 2009 ). In our own research, we have routinely shown similarly high rates of smoking among methamphetamine-dependent individuals (De La Garza et al., 2008 , 2009 De La Garza et al. ; Newton et al. ; Zorick et al., 2009 ). Compared to smokers alone, smokers with co-morbid substance use disorders are at greater risk of suffering from smoking-related death (Hser et al., 1994; Hurt et al., 1996) . While the cause of increased negative health outcomes is unknown, likely reasons are that co-morbid smokers are a more treatment-resistant population (using more drug more frequently, earlier initiation, etc.) and there may be additive effects of combining two drugs with known negative health effects (Weinberger and Sofuoglu, 2009 ). The U.S. Department of Health and Human Services Clinical Practice Guidelines explicitly recommends addressing cigarette smoking in treatments for substance dependence (Fiore et al., 2008) . However, relatively few studies have examined smoking cessation treatments for those with stimulant dependence (Morisano et al., 2009; Weinberger and Sofuoglu, 2009 ). In many addiction treatment settings, smoking is actually endorsed in the form of regular smoke breaks (Knapp et al., 1993) ; a strategy apparently adopted by treatment providers concerned that reducing smoking may impede successful treatment outcomes. However, a meta-analysis of smoking interventions in addiction treatment settings suggests smoking cessation treatments may actually enhance longer-term addiction outcomes (Prochaska et al., 2004) .
Among the general population of smokers, millions attempt to quit smoking each year, but the majority of those who attempt to quit on their own fail within 8 days of the initial quit attempt (Hughes et al., 2004) . Currently, first-line pharmacotherapies for smoking cessation include nicotine replacement therapy, bupropion, and varenicline. These medications consistently improve smoking cessation rates relative to placebo in randomized control trials, however rates of abstinence are only 20-33% at 6-months after the initial quit attempt (Fiore et al., 2008) . Therefore, it is important to continue the search for new pharmacotherapies to mitigate withdrawal symptoms and prevent relapse during smoking cessation.
Substantial evidence points to nicotine as the primary agent in tobacco leading to abuse and dependence (Dwoskin et al., 2009; Govind et al., 2009; Livingstone and Wonnacott, 2009 
